Evogene Partners with Unravel to Tackle Demyelinating Disease with AI-Driven Drug Design
Event summary
- Evogene and Unravel Biosciences have initiated a collaboration to develop a first-in-class therapy for demyelinating disorders, including Multiple Sclerosis.
- The partnership leverages Evogene's ChemPass AI generative chemistry platform and Unravel's BioNAV™ predictive biology platform and Living Molecular Twins™ patient datamine.
- Unravel's platform has identified a novel demyelination target, which Evogene will use to design and optimize small-molecule inhibitors.
- The collaboration aims to restore myelin and improve neurological function, an area where current therapies have limited efficacy.
The big picture
The collaboration represents a growing trend of combining AI-driven target identification with generative chemistry to accelerate drug discovery, particularly in areas with high unmet need like neurodegenerative diseases. The global market for MS therapies exceeds $13 billion annually, and the lack of effective myelin repair therapies creates a significant opportunity for a breakthrough treatment. Evogene's reliance on Unravel's target validation introduces a degree of dependency, but also potentially de-risks their generative AI platform.
What we're watching
- Clinical Validation
- The success of this collaboration hinges on Unravel’s ability to validate the novel target and demonstrate efficacy in preclinical models, a historically challenging area for demyelination therapies.
- ChemPass AI
- The effectiveness of Evogene’s ChemPass AI in designing brain-penetrant molecules that effectively target the identified mechanism will be critical to the program's advancement.
- Regulatory Pathway
- Given the complexity of neurological disorders and the potential for novel mechanisms of action, the regulatory pathway for any resulting therapy will likely be lengthy and require significant data to support approval.
Related topics